Related Experiment Videos
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
1Rheumatology Division, Cabrini Medical Center, New York, USA.
Geriatrics
|March 25, 2000
Summary
New treatments for rheumatoid arthritis (RA) include disease-modifying agents like etanercept, leflunomide, and infliximab. Selective cyclooxygenase-2 (COX-2) inhibitors offer NSAID-like relief with reduced gastrointestinal and platelet toxicity.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) treatment is evolving with deeper insights into its pathophysiology.
- Recent advancements have led to new therapeutic options for early RA intervention.
Purpose of the Study:
- To review the latest treatment options for rheumatoid arthritis.
- To highlight newly approved disease-modifying agents and cyclooxygenase-2 (COX-2) inhibitors.
Main Methods:
- Review of recently approved medications for rheumatoid arthritis.
- Analysis of the efficacy and safety profiles of new RA treatments.
Main Results:
- Etanercept, leflunomide, and infliximab are newly approved disease-modifying agents for early RA intervention.
- Selective COX-2 inhibitors provide RA symptom relief comparable to traditional NSAIDs.
- COX-2 inhibitors demonstrate reduced gastrointestinal and platelet toxicity compared to NSAIDs.
Conclusions:
- The expanding treatment landscape for RA offers improved options for patients.
- Selective COX-2 inhibitors represent a safer alternative for managing RA symptoms.